Results 21 to 30 of about 721 (165)

Treatment of High Dose Methotrexate Toxicity with Glucarpidase [PDF]

Journal of Clinical Toxicology, 2016
High Dose Methotrexate (HD-MTX) toxicity can cause renal dysfunction in patients due to a presence of risk factors such as body mass index >25 kg/m2, comedication (salicylates, NSAID`s, sulfonamides, beta-lactam antibiotics, aminoglycosides), urine pH<7, iv fluid intake <3 l/m2/24 hours, hepatic dysfunction, renal insufficiency prior to HD-MTX,
Mitrovic, Darco, Touw, Daan J., Tissing, W.   +2 more
openaire   +5 more sources

Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients [PDF]

Pediatric Blood and Cancer, 2015
BackgroundGlucarpidase rapidly reduces methotrexate plasma concentrations in patients experiencing methotrexate‐induced renal dysfunction. Debate exists regarding the role of glucarpidase in therapy given its high cost. The use of reduced‐dose glucarpidase has been reported, and may allow more institutions to supply this drug to their patients.
Alejandro R Molinelli, Fariba Navid, Mary V Relling   +2 more
exaly   +3 more sources

High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights [PDF]

Frontiers in Medicine
High-dose methotrexate (HD-MTX) toxicity represents a significant clinical challenge in oncology, commonly resulting in acute kidney injury (AKI), myelosuppression, and potentially life-threatening multiorgan failure.
Ana Carolina Nakamura Tome, Karise Fernades Santos, Emerson Quintino Lima, Rodrigo Jose Ramalho   +3 more
doaj   +2 more sources

Reply to: Methotrexate toxicity and glucarpidase: A call for dose optimization. Koppen A, et al. Br J Clin Pharmacol. 2025;91(5):1289-1292 doi:10.1002/bcp.70044. [PDF]

Br J Clin Pharmacol
British Journal of Clinical Pharmacology, Volume 91, Issue 9, Page 2762-2763, September 2025.
Rizzari C, Schwartz S.
europepmc   +2 more sources

P1135: EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY [PDF]

HemaSphere, 2023
Sabrina Pierre, Maël Heiblig, Mikaïl Nourredine, Guillaume Grenet, Kevin Bihan, Thierry Vial   +5 more
doaj   +2 more sources

Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study

BMC Cancer, 2022
Background High-dose methotrexate (HD-MTX) has broad use in the treatment of central nervous system (CNS) malignancies but confers significant toxicity without inpatient hydration and monitoring. Glucarpidase is a bacterial recombinant enzyme dosed at 50 
Lauren R. Schaff, Mina Lobbous, Dean Carlow, Ryan Schofield, Igor T. Gavrilovic, Alexandra M. Miller, Jacqueline B. Stone, Anna F. Piotrowski, Ugur Sener, Anna Skakodub, Edward P. Acosta, Kevin J. Ryan, Ingo K. Mellinghoff, Lisa M. DeAngelis, Louis B. Nabors, Christian Grommes   +15 more
doaj   +1 more source

Charcoal Hemoperfusion for Methotrexate Toxicity: A Safe and Effective Life-Rescue Alternative When Glucarpidase Is Not Available

Frontiers in Pediatrics, 2021
Background: High dose methotrexate (HDMTX) is used for the treatment of pediatric hemato-oncological diseases. HDMTX can induce acute kidney injury in cases of delayed elimination. The use of leucovorin remains the most effective rescue action.
Alejandra Rosales, Alvaro Madrid, Marina Muñoz, Jose Luis Dapena, Jose Luis Dapena, Gema Ariceta   +5 more
doaj   +1 more source

Methotrexate nephrotoxicity in a patient with preserved renal function. Case report [PDF]

, 2022
Introducción: El metotrexato es un fármaco con propiedades quimioterapéuticas usa-do de forma frecuente para el tratamiento de ciertos tipos de cáncer. A continuación, se presenta un caso clínico que, a conocimiento de los autores, es el primer reporte ...
Ardila Hani, Carolina, García Padilla, Paola Karina, Ríos Valbuena, Juan José   +2 more
core   +2 more sources

Incidence and management of patients with methotrexate delayed elimination in the clinical practice : A Delphi study [PDF]

, 2023
High-dose methotrexate (HDMTX) is administered for the treatment of some cancers. HDMTX is usually safe but may crystallize in renal tubules causing acute kidney injury (AKI).
Badia, Xavier, Cabero-Martínez, Almudena, de la Fuente, Adolfo, del Cerro, Inés, Domínguez-Pinilla, Nerea, Gallardo, Eva, Giró-Perafita, Ariadna, González Barca, Eva, Gros, Luis, Roldán, Alicia, Tasso, María, Torrent, Montserrat, Universitat Autònoma de Barcelona   +12 more
core   +1 more source

Pharmacokinetics as a Biomarker. [PDF]

Clin Transl Sci
ABSTRACT Pharmacokinetics (PK) has long been differentiated from pharmacodynamics (PD) and biomarkers, yet this distinction undervalues PK's translational relevance. In this Perspective, we propose that PK itself functions as a biomarker that bridges dose, exposure, and response. Using examples from target‐mediated drug disposition, antidrug antibodies,
Wagner JA, Singh S, Taylor ZL.
europepmc   +2 more sources